ALLMedicine™ Alopecia Universalis Center

Nov 7th, 2022 - Alopecia Areata (AA) is a T-cell mediated autoimmune attack on hair follicles resulting in rapidly developing areas of hair loss involving the scalp and beard that can progress to total scalp hair loss (alopecia totalis) and loss of eyebrows, eyel...

Oct 1st, 2022 - Tofacitinib is a pan-janus kinase inhibitor (JAK) which has been tested off-label in alopecia areata (AA) with promising results. However, evidence of tofacitinib in real-life setting is still poor. We evaluated long-term efficacy and safety of to...

Sep 22nd, 2022 - Alopecia areata (AA) is a common autoimmune disease that results in loss of body hair in varying degrees. The condition is estimated to affect more than 6.5 million people in the United States alone (naaf.org), with a worldwide prevalence of 0.1% ...

Aug 16th, 2022 - Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired demyelinating disease of the peripheral nervous system with unknown etiology. Alopecia universalis, an advanced form of alopecia areata (AA), is a condition characterized by c...

Aug 11th, 2022 - This is a multi-center Phase 2 study to evaluate the safety and effectiveness of an investigational drug in adults (≥18 years and ≤65 years) who have 50% or greater scalp hair loss, including alopecia totalis (AT) and alopecia universalis (AU).

Sep 22nd, 2022 - Alopecia areata (AA) is a common autoimmune disease that results in loss of body hair in varying degrees. The condition is estimated to affect more than 6.5 million people in the United States alone (naaf.org), with a worldwide prevalence of 0.1% ...

Aug 11th, 2022 - This is a multi-center Phase 2 study to evaluate the safety and effectiveness of an investigational drug in adults (≥18 years and ≤65 years) who have 50% or greater scalp hair loss, including alopecia totalis (AT) and alopecia universalis (AU).

Mar 21st, 2022 - Alopecia areata (AA) is an autoimmune condition resulting in chronic and relapsing hair loss. AA patchy is associated with well-circumscribed patches of hair loss, commonly on the scalp or face, while alopecia totalis (AT) and alopecia universalis...

Apr 6th, 2021 - Alopecia areata (AA) is a common autoimmune disease that triggers non scarring hair loss in different severities. Usually the hair loss will be contained to the scalp and / or beard, but in some cases, there will be total hair loss from the entire...

Mar 11th, 2021 - Alopecia areata is a medical condition, in which the hair falls out in patches. The hair can fall out on the scalp or elsewhere on the face and body. Alopecia areata is an autoimmune skin disease, which means that the immune system is recognizing ...

Aug 9th, 2022 - Alopecia areata (AA) is an autoimmune disorder characterized by transient hair loss with preservation of the hair follicle (HF). The lifetime incidence risk of AA is approximately 2%,1 with a mean age of onset of 25 to 36 years and with no clinica.

May 5th, 2022 - The findings of smooth, round alopecia occurring rapidly without associated scarring, pain, or itching, is consistent with the diagnosis of alopecia areata. Alopecia areata is a common autoimmune disease caused by T lymphocytes targeting hair foll.

Oct 4th, 2021 - Baricitinib, an oral inhibitor of Janus kinase (JAK) types 1 and 2, produced substantial rates of hair growth with acceptable tolerability for patients with alopecia areata, according to the results of two phase 3 trials presented at the European ...

Aug 19th, 2021 - Patients with alopecia areata (AA) appear to have a gut dysbiosis not seen in healthy individuals, according to research presented at the annual meeting of the Society for Investigative Dermatology. There have been reports of gut microbiome dysbio.

Jan 7th, 2020 - Cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) is a key co-stimulatory receptor expressed on activated T cells that negatively regulates T-cell activation. 1-3 It exerts its effects in part by the prevention of IL-2 transcription and inhibiti.